Showing results (61-70 of 96) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2020
Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic ModelInhye E Ahn, Xin Tian, David Ipe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2017
Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse ModelCarsten U Niemann, Helena I Mora-Jensen, Eman L Dadashian, et al.
Blood|March 8, 2011
The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemiaSarah E M Herman, Rosa Lapalombella, Amber L Gordon, et al.
Blood|March 23, 2011
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765Sarah E M Herman, Amber L Gordon, Erin Hertlein, et al.
Leukemia & Lymphoma|November 16, 2021
CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantageArshia Soleimani, Alba Navarro, Delong Liu, et al.
The AAPS Journal|September 8, 2012
Pharmacokinetics and tissue disposition of lenalidomide in miceDarlene M Rozewski, Sarah E M Herman, William H Towns, et al.
Blood|May 11, 2018
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib eraHannah R Robinson, Junpeng Qi, Erika M Cook, et al.
Leukemia|April 27, 2013
Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapyS E M Herman, X Sun, E M McAuley, et al.
Blood Advances|March 31, 2022
The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemiaClare Sun, Yun-Ching Chen, Aina Martinez Zurita, et al.
Blood|November 21, 2012
Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemiaBo Yu, Yicheng Mao, Li-Yuan Bai, et al.
Pageof 10